The second quarter performance pressure in Pharmaceutical was far more severe for Roche vs. Novartis. However, other than the impact of the Q1 forward-buying reversal, Roche was also impacted by the accelerated decline of the older and off-patent oncology trio. Fortunately, Diagnostics render a valued cushion, thanks to the group’s COVID-19 test offering. While Roche’s top-line is somewhat vulnerable to biosimilar risks, despite an impressive pipeline, its profitability prowess an
